AC Immune Company Insiders

ACIU Stock  USD 3.54  0.06  1.72%   
AC Immune employs about 133 people. The company is managed by 23 executives with a total tenure of roughly 34 years, averaging almost 1.0 years of service per executive, having 5.78 employees per reported executive. Breaking down AC Immune's management performance can provide insight into the firm performance.
Andrea Pfeifer  CEO
CEO CoFounder
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.

AC Immune Management Team Effectiveness

The company has return on total asset (ROA) of (0.2197) % which means that it has lost $0.2197 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7463) %, meaning that it created substantial loss on money invested by shareholders. AC Immune's management efficiency ratios could be used to measure how well AC Immune manages its routine affairs as well as how well it operates its assets and liabilities.
AC Immune secures a total of 100.6 Million outstanding shares. AC Immune shows tangible amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.

AC Immune Workforce Comparison

AC Immune is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,425. AC Immune holds roughly 133 in number of employees claiming about 9% of equities under Health Care industry.

AC Immune Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. AC Immune Price Series Summation is a cross summation of AC Immune price series and its benchmark/peer.

AC Immune Notable Stakeholders

An AC Immune stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AC Immune often face trade-offs trying to please all of them. AC Immune's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AC Immune's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Andrea PfeiferCEO CoFounderProfile
Oliver MDVP DevelopmentProfile
Julian SnowVP DevelopmentProfile
Nuno MDChief OfficerProfile
Christopher RobertsInterim FinProfile
Gnther StafflerInterim DevelopmentProfile
Mark DantonExecutive IntelligenceProfile
Sonia PoliHead ScienceProfile
Matthias MaurerSenior CounselProfile
Piergiorgio DonatiChief OfficerProfile
Anke MDChief OfficerProfile
Pr MDChief OfficerProfile
Joshua DrummHead RelationsProfile
JeanFabien MoninChief Administrative OfficerProfile
Howard DonovanChief OfficerProfile
Alexandre CaratschGeneral CounselProfile
Gary WaandersSenior CommunicationsProfile
Marie KoscoVilboisChief OfficerProfile
Julien RongereSenior AssuranceProfile
Judith MooreGlobal CommunicationsProfile
Madiha DerouaziChief OfficerProfile
Joseph WettsteinHead OfficerProfile
David HickmanHead SMEProfile
String symbol = request.getParameter("s");

About AC Immune Management Performance

The success or failure of an entity such as AC Immune often depends on how effective the management is. AC Immune management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ACIU management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ACIU management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland. AC Immune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Please note, the imprecision that can be found in AC Immune's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AC Immune. Check AC Immune's Beneish M Score to see the likelihood of AC Immune's management manipulating its earnings.

AC Immune Workforce Analysis

Traditionally, organizations such as AC Immune use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AC Immune within its industry.

AC Immune Manpower Efficiency

Return on AC Immune Manpower

Revenue Per Employee205.3K
Revenue Per Executive1.2M
Net Loss Per Employee382.8K
Net Loss Per Executive2.2M
Working Capital Per Employee535K
Working Capital Per Executive3.1M

Additional Tools for ACIU Stock Analysis

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.